| | | | | | | | | | |
|
|
| Dockets Entered
On January 19, 2006
Tableof Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
| 2000P-0586
|
| Amend Pt 133.3 re:Milk and Nonfat Milk for use in Standardiz
|
|
|
| 2002N-0273
|
| Animal Proteins Prohibited in Ruminant Feed
|
|
|
| 2003P-0132
|
| Part 135 FDA regulations standard of identity frozen dessert
|
|
|
| 2004H-0322
|
| Civil Money Penalty Re: Ecumed Health Group, Inc.
|
|
|
| 2005N-0262
|
| Submission of Chemistry, Manufacturing, and Controls Information in a New Drug Application Under the New Pharmaceutical Quality Assessment System; Notice of Pilot Program
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
| 2006N-0010
|
| Able Laboratories, Inc.; Withdrawal of Approval of 43 Abbreviated New Drug Applications
|
|
|
| 2006P-0039
|
| FDA issue new labeling requirements for caffeinated food products
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
| LET
17139
|
| Sedona Labs, Inc.
|
| Vol #:
|
| 155
|
|
|
| LET
17140
|
| Enzymatic Therapy
|
| Vol #:
|
| 155
|
|
|
| LET
17141
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17142
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17143
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17144
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17145
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17146
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17147
|
| Univera, Inc.d.b.a. Oasis LifeSciences
|
| Vol #:
|
| 156
|
|
|
| LET
17148
|
| American Healing Technologies, Inc.
|
| Vol #:
|
| 156
|
|
|
| LET
17149
|
| American Healing Technologies, Inc.
|
| Vol #:
|
| 156
|
|
|
| LET
17150
|
| Futurebiotics LLC
|
| Vol #:
|
| 156
|
|
|
| LET
17151
|
| Futurebiotics LLC
|
| Vol #:
|
| 156
|
|
|
| LET
17152
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17153
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17154
|
| Natrol, Inc.
|
| Vol #:
|
| 156
|
|
|
| LET
17155
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17156
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17157
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17158
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17159
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17160
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17161
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17162
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17163
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
| | | | | | | | |
|
|
| LET
17164
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| LET
17165
|
| Enzymatic Therapy
|
| Vol #:
|
| 156
|
|
|
| 2000P-0586
|
| Amend Pt 133.3 re:Milk and Nonfat Milk for use in Standardiz
|
|
|
| C
86
|
| National Family Farm Coalition (NFFC)
|
| Vol #:
|
| 2
|
|
|
| C
87
|
| Daisy Brand, Inc. (Daisy Brand)
|
| Vol #:
|
| 2
|
|
|
| C
88
|
| National Farmers Union (NFU)
|
| Vol #:
|
| 2
|
|
|
| C
89
|
| Government of Mexico
|
| Vol #:
|
| 2
|
|
|
| C
90
|
| Fonterra (USA), Inc.
|
| Vol #:
|
| 27
|
|
|
| 2002N-0273
|
| Animal Proteins Prohibited in Ruminant Feed
|
|
|
| C
526
|
| Maury County Government
|
| Vol #:
|
| 45
|
|
|
| C 527
|
| J. Todt et al.
|
| Vol #:
|
| 45
|
|
|
| C 528
|
| D. Vauprau
|
| Vol #:
|
| 45
|
|
|
| LET
8
|
| Honorable Nathaniel S. Berry
|
| Vol #:
|
| 45
|
|
|
| LET
9
|
| Honorable Barbara A. Mikulski
|
| Vol #:
|
| 45
|
|
|
| 2003P-0132
|
| Part 135 FDA regulations standard of identity frozen dessert
|
|
|
| C 46
|
| P. Molnau
|
| Vol #:
|
| 2
|
|
|
| C 47
|
| P. Nesbit
|
| Vol #:
|
| 2
|
|
|
| 2004H-0322
|
| Civil Money Penalty Re: Ecumed Health Group, Inc.
|
|
|
| LET
9
|
| Ecumed Health Group and Amador Reyes, Juan C. Carrai, Richard W. Stone,M.D. & Erlinda B. Enriq
|
| Vol #:
|
| 10
|
|
|
| 2005N-0262
|
| Submission of Chemistry, Manufacturing, and Controls Information in a New Drug Application Under the New Pharmaceutical Quality Assessment System; Notice of Pilot Program
|
|
|
| LET 5
|
| GlaxoSmithKline (GSK)
|
| Vol #:
|
| 4
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
| C 290
|
| J. Mosley
|
| Vol #:
|
| 3
|
|
|
| C 291
|
| S. Brasch
|
| Vol #:
|
| 3
|
|
|
| C 292
|
| L. Fagert, RN,BSN,MSN
|
| Vol #:
|
| 3
|
|
|
| C 293
|
| D. Miller
|
| Vol #:
|
| 3
|
|
|
| C 294
|
| S. Goin
|
| Vol #:
|
| 3
|
|
|
| C 295
|
| E. McBroom
|
| Vol #:
|
| 3
|
|
|
| C 296
|
| M. Frasure
|
| Vol #:
|
| 3
|
|
|
| C 297
|
| N. Bargen
|
| Vol #:
|
| 3
|
|
|
| C 298
|
| B. Berg
|
| Vol #:
|
| 3
|
|
|
| C 299
|
| J. Engelbach
|
| Vol #:
|
| 3
|
|
|
| C 300
|
| B. Fetner
|
| Vol #:
|
| 3
|
|
| | | | | | | |
|
|
| C 301
|
| N. DeLong
|
| Vol #:
|
| 3
|
|
|
| C 302
|
| C. Falstrom
|
| Vol #:
|
| 3
|
|
|
| C 303
|
| P. Shea
|
| Vol #:
|
| 3
|
|
|
| C 304
|
| B. Gray
|
| Vol #:
|
| 3
|
|
|
| C 305
|
| D. Bobbitt
|
| Vol #:
|
| 3
|
|
|
| C 306
|
| E. Allshouse
|
| Vol #:
|
| 3
|
|
|
| C 307
|
| J. Howse
|
| Vol #:
|
| 3
|
|
|
| C 308
|
| B. Haskins
|
| Vol #:
|
| 3
|
|
|
| C 309
|
| M. Olinde
|
| Vol #:
|
| 3
|
|
|
| C 310
|
| R. Long
|
| Vol #:
|
| 3
|
|
|
| C 311
|
| L. Karg
|
| Vol #:
|
| 3
|
|
|
| C 312
|
| B. Glassill
|
| Vol #:
|
| 3
|
|
|
| C 313
|
| D. Foord
|
| Vol #:
|
| 3
|
|
|
| C 314
|
| P. Patterson
|
| Vol #:
|
| 3
|
|
|
| C 315
|
| E. Allshouse
|
| Vol #:
|
| 3
|
|
|
| C 316
|
| J. Howse
|
| Vol #:
|
| 3
|
|
|
| C 317
|
| D. Mowitz
|
| Vol #:
|
| 3
|
|
|
| C 318
|
| G. Clarke
|
| Vol #:
|
| 3
|
|
|
| C 319
|
| D. Vadeboncouer
|
| Vol #:
|
| 3
|
|
|
| C 320
|
| J. Heinrich
|
| Vol #:
|
| 3
|
|
|
| C 321
|
| D. Parker
|
| Vol #:
|
| 3
|
|
|
| C 322
|
| R. Minor, M.D.
|
| Vol #:
|
| 3
|
|
|
| C 323
|
| D. Ferell
|
| Vol #:
|
| 3
|
|
|
| C 324
|
| N. Peterson
|
| Vol #:
|
| 3
|
|
|
| C 325
|
| A. Hollar
|
| Vol #:
|
| 3
|
|
|
| C 326
|
| K. Balzario
|
| Vol #:
|
| 3
|
|
|
| C 327
|
| S. Peterson
|
| Vol #:
|
| 3
|
|
|
| C 328
|
| M. Rogers
|
| Vol #:
|
| 3
|
|
|
| C 329
|
| A. Nizzardi
|
| Vol #:
|
| 3
|
|
|
| C 330
|
| L. Sigmon
|
| Vol #:
|
| 3
|
|
|
| C 331
|
| L. Bell
|
| Vol #:
|
| 3
|
|
|
| C 332
|
| N. Codding
|
| Vol #:
|
| 3
|
|
|
| C 333
|
| J. Conaway
|
| Vol #:
|
| 3
|
|
|
| C 334
|
| N. Thomats
|
| Vol #:
|
| 3
|
|
|
| C 335
|
| K. Simrin
|
| Vol #:
|
| 3
|
|
|
| C 336
|
| J. Gallimore
|
| Vol #:
|
| 3
|
|
|
| C 337
|
| G. Millins, MD
|
| Vol #:
|
| 3
|
|
| | | | | | | | |
|
|
| C 338
|
| S. Smith
|
| Vol #:
|
| 3
|
|
|
| C 339
|
| C.Lawrence
|
| Vol #:
|
| 3
|
|
|
| C 340
|
| P. Kimbrel
|
| Vol #:
|
| 3
|
|
|
| C 341
|
| S. Isbell
|
| Vol #:
|
| 3
|
|
|
| 2006N-0010
|
| Able Laboratories, Inc.; Withdrawal of Approval of 43 Abbreviated New Drug Applications
|
|
|
| NWL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2006P-0039
|
| FDA issue new labeling requirements for caffeinated food products
|
|
|
| ACK
1
|
| HFA-305 to Food and Drug Law Class
|
| Vol #:
|
| 1
|
|
|
| CP
1
|
| Food and Drug Law Class
|
| Vol #:
|
| 1
|
|
|